Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

On Friday 4 October, Professor David Taggart from the Nuffield Department of Surgical Sciences (NDS) presented the results of the VEST III trial at the 2019 European Cardio-Thoracic Surgery annual meeting in Lisbon, Portugal.

The VEST III is a randomized controlled trial that enrolled 184 patients in 14 centres in Germany, Austria, Israel and the UK. At two years, the trial met its primary and secondary endpoints showing superior perfect patency rates (Fitzgibbon I) of externally stented vein grafts compared to the control group (66.4% vs 53.6%, p value = 0.02) and a highly significant reduction of 25% (p value <0.001) in both intimal area and thickness assessed by intravascular ultrasound.

"The results of the VEST III trial confirm our previous observations regarding the bio-mechanical effects of external stenting," said Professor Taggart who leads the Cardiac Surgery Trials Group in NDS. "This is another milestone in our ongoing efforts to improve coronary surgery and patients' quality of life. As the principle investigator of the first in man VEST I trial in 2011, and who has closely followed the evolution of this technology in the last 10 years, it is very satisfying to see how the combined effort of surgeons, scientists and innovators has led to a technology with high clinical impact."

Similar stories

EndoNET randomises first patient of 2023

A trial investigating how effective endocrine treatment is, prior to surgery in post-menopausal women with breast cancer, has randomised its first patient of the year.

New Cochrane review on antihistamines for motion sickness

A new systematic review from Cochrane ENT at the Nuffield Department of Surgical Sciences says antihistamines are likely to reduce the risk of developing motion sickness (travel sickness) in susceptible adults under naturally occurring conditions of movement, but they may be more likely to cause drowsiness than placebo.

Life-changing results from DRWF Human Islet Isolation Facility at NDS

A new documentary film launched by the Diabetes Research and Wellness Foundation (DRWF) on World Diabetes Day 2022 features an interview with Professor Paul Johnson, as he describes life-changing results from the DRWF Human Islet Isolation Facility at the Nuffield Department of Surgical Sciences (NDS).

Blog posts

Staff Census: We need you!

All Medical Sciences staff are invited to log into HR self-service and ensure their contact, diversity background and disability details are up to date. Between 6% and 27% of staff in the Division are missing their diversity data which makes it difficult to complete statutory reporting, understand or track our population changes and to plan actions around staff diversity and equality – make sure your data is complete today!

Oxford MedSci goes silver: 10 Years of Athena SWAN

The Medical Sciences Division is celebrating 10 years since its first Athena Swan bronze application, and the first year in which all 16 of its departments have achieved a silver award. The silver award recognises commitment to gender equality, understanding culture and context, and more. Read about our department’s hard work and innovation.

Lights, camera, action! My journey into video production

Dr Hannah McGivern provides a 'behind-the-scenes' account of her experience producing the video 'Journey of a QUOD Sample: Donating to Transplant Research', supported by the funds from the University of Oxford Public Engagement with Research (PER) Seed Fund.